User profiles for Katharine A. Collier

Katharine Collier

Assistant Professor, Ohio State University
Verified email at osumc.edu
Cited by 577

Clinical activity and safety of cabozantinib for brain metastases in patients with renal cell carcinoma

…, DA Braun, N Rathi, J Thouvenin, KA Collier… - JAMA …, 2021 - jamanetwork.com
Importance Patients with brain metastases from renal cell carcinoma (RCC) have been
underrepresented in clinical trials, and effective systemic therapy is lacking. Cabozantinib shows …

[HTML][HTML] Targeting BET bromodomain proteins in solid tumors

V Sahai, AJ Redig, KA Collier, FD Eckerdt… - Oncotarget, 2016 - ncbi.nlm.nih.gov
There is increasing interest in inhibitors targeting BET (bromodomain and extra-terminal)
proteins because of the association between this family of proteins and cancer progression. …

[HTML][HTML] A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNA

…, JB Hiatt, RD Patton, N De Sarkar, KA Collier… - Nature …, 2022 - nature.com
Cell-free DNA (cfDNA) has the potential to inform tumor subtype classification and help guide
clinical precision oncology. Here we develop Griffin, a framework for profiling nucleosome …

[HTML][HTML] A comprehensive review of heregulins, HER3, and HER4 as potential therapeutic targets in cancer

JM Mota, KA Collier, RLB Costa, T Taxter, A Kalyan… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Heregulins (HRGs) bind to the receptors HER3 or HER4, induce receptor dimerization, and
trigger downstream signaling that leads to tumor progression and resistance to targeted …

[HTML][HTML] Acquired resistance to poly (ADP-ribose) polymerase inhibitor olaparib in BRCA2-associated prostate cancer resulting from biallelic BRCA2 reversion …

BA Carneiro, KA Collier, RJ Nagy… - JCO precision …, 2018 - ncbi.nlm.nih.gov
Mutations of the BRCA1 or BRCA2 gene (BRCA1/2) confer an increased lifetime risk of
developing breast, ovarian, pancreatic, and prostate cancers, among others. 1, 2 BRCA1/2-…

[HTML][HTML] Metastatic renal cell carcinoma to the pancreas and other sites—a multicenter retrospective study

…, J Panian, N Weise, N Dizman, KA Collier… - …, 2023 - thelancet.com
Background Metastatic renal cell carcinoma (mRCC) is a heterogenous disease with poor 5-year
overall survival (OS) at 14%. Patients with mRCC to endocrine organs historically have …

[HTML][HTML] Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells

K Ebine, K Kumar, TN Pham, MA Shields, KA Collier… - Scientific reports, 2018 - nature.com
The fibrotic reaction is a characteristic feature of human pancreatic ductal adenocarcinoma (PDAC)
tumors. It is associated with activation and proliferation of pancreatic stellate cells (…

A multicenter study assessing survival in patients with metastatic renal cell carcinoma receiving immune checkpoint inhibitor therapy with and without cytoreductive …

…, JA Thompson, A Parikh, Y Yang, KA Collier… - … Oncology: Seminars and …, 2023 - Elsevier
Background Cytoreductive nephrectomy (CN) for the treatment of metastatic renal cell carcinoma
(mRCC) was called into question following the publication of the CARMENA trial. While …

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas

DB Welling, KA Collier, SS Burns… - Laryngoscope …, 2021 - Wiley Online Library
Objectives Two pilot studies of AR‐42, a pan‐histone deacetylase inhibitor, in human
neurofibromatosis type 2 (NF2), vestibular schwannomas (VS), and meningiomas are presented. …

A phase 1 trial of the histone deacetylase inhibitor AR-42 in patients with neurofibromatosis type 2-associated tumors and advanced solid malignancies

KA Collier, H Valencia, H Newton, EM Hade… - Cancer chemotherapy …, 2021 - Springer
Purpose Given clinical activity of AR-42, an oral histone deacetylase inhibitor, in hematologic
malignancies and preclinical activity in solid tumors, this phase 1 trial investigated the …